Skip to content
DraconiticResearch
Search Sources API
206,690 studies31 sourcesUpdated 44 min ago

Oncology

5,185 studies511 in 7 days2,486 in 30 days

Filters
Type
Date
Clear

Latest

5,185 studies

  1. Development and internal validation of an interpretable mammography-based model for malignancy risk stratification in BI-RADS 4 breast lesions
    Yanheng Zhang, Nan Ding, Tingting Jiao +1
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  2. Preoperative frailty risk in older patients with colorectal cancer admitted to the ICU after surgery: prevalence, associated factors, and association with in-hospital outcomes
    Yongqin Wang, Guifang Li, Qiuyan Yang +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  3. Case Report: Malignant solitary fibrous tumor of the greater omentum
    Dongliang Zhong, Jun Ji, Jiaxin Li
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  4. Prolonged survival after small-cell transformation of EGFR-mutant lung adenocarcinoma: a case report
    Yaxin Yan, Dongjie Du, Fenghua Wen +2
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  5. Primary resistance to afatinib in a patient with NSCLC harboring EGFR p.E709_T710delinsD and brain metastases: a case report and literature review
    Su-Su Dong, Xuan Zhang, Wen Dong
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  6. ORC1 expression features and its prognostic significance in HBV-associated hepatocellular carcinoma
    Rong Xie, Qing-Mei Li, Hang Wang +10
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  7. Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d’Ivoire
    Bitti Addé Odo, Kouame Konan Yvon Kouassi, Pétiori Gningayou Laurence Toure +11
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  8. Subtype or state? Rethinking the apCAF paradox and fibroblast plasticity in gastrointestinal cancers
    Zhilin Yu, Dingnan Hu, Zhenxiang An
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  9. Clinical characteristics and prognosis of liver injury in patients receiving immune checkpoint inhibitor-based therapy: a real-world retrospective study
    Liang Gao, Xiaotian Yang, Fengkun Yang +6
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefDOAJ
  10. The Association Between Asthma and Pancreatic Cancer: A Systematic Review
    Basel Darawsha, Harish Lavu, Charles J. Yeo +2
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  11. Precision Perioperative Treatment for Resectable Non-Small Cell Lung Cancer: Current Status and Perspectives
    Dayna J. Isaacs, Cathleen J. Park, Linjun Zha +7
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  12. The Changing Global Epidemiology of Early-Onset Colorectal Cancer: Incidence Trends, Modifiable Risk Factors, and Future Burden Projections
    Kacper Wrzosek, Agata Koba, Pola Bakalczuk +7
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  13. Immune Cell Landscape in the NSCLC Tumour Microenvironment: Molecular Dysregulation, Crosstalk and Insights into the CEMIP-STAT3-Mediated Immunosuppressive Axis
    Lanqing Wang, Sisi Yan, Fajian He +2
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  14. Identification of Candidate Partner Cells in Tumor–Stromal Interactions by Histology-Based Spatial Analysis for Prognostic Stratification After Neoadjuvant Chemotherapy
    Naing Ye Aung, Takanobu Kabasawa, Yuki Hamada +2
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  15. Interpreting the Early Cancer Peak in Immune-Mediated Inflammatory Diseases. Comment on Giordani et al. Cancer Association in Patients with Immune-Mediated Inflammatory Diseases: A Five-Year Nationwide Italian Cohort Study. Cancers 2026, 18, 1027
    Alper Gumustepe, Esra Gumustepe
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  16. Plant-Derived Bioactive Compounds, Cancer Stemness and Cellular Senescence: A Narrative Review of Preclinical Evidence and Translational Relevance to Cancer Recurrence and Drug Resistance
    Sara Naseer, Wai-Yann Tan, Yin-Teng Sow +5
    NutrientsPeer-reviewedCC BY 4.0OncologyCrossref
  17. Cancer Incidence and Survival Among Ever-Incarcerated Patients in California and Massachusetts
    Christopher R. Manz, Angela C. Tramontano, Samira L. Dias +4
    JAMA Network OpenPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossrefPMC
  18. Cancer Screening, Diagnosis, and Survival in California Prisons
    Christopher R. Manz, Angela C. Tramontano, Emma Voligny +9
    JAMA Network OpenPeer-reviewedCC BY-NC-ND 4.0Full text1 citedOncologyCrossrefPMC
  19. Cancer incidence following platelet count and C-reactive protein testing across ethnic groups in English primary care: a cohort study of 5 million patients
    Melissa Barlow, Liz Down, Luke T A Mounce +4
    BMJ OpenPeer-reviewedCC BY 4.0Full textOncologyCrossrefPMC
  20. Cancer-associated fibroblasts: multifaceted regulators of the tumor microenvironment and emerging therapeutic targets
    Jinsong Yu, Han Yang, Xiaofang Zhu
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0OncologyCrossref
  21. Spatial immune architecture and immunotherapy resistance in microsatellite-stable colorectal cancer
    Xianwei Liu, Qiangming Liao, Yuan Cheng +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  22. POSTN-expressing cancer-associated fibroblasts: roles in the tumor microenvironment and clinical implications
    Xiufang Wang, Yongchang Zhao
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  23. Integrative pan-cancer and clinical cytokine profiling reveals a pro-inflammatory cytokine index for colon cancer peritoneal metastasis and immunotherapy response
    Caihong Wu, Xin Li, Dan Wang +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  24. CXCR2 associated neutrophil stromal interactions and immune exclusion in microsatellite stable colorectal cancer
    Ting Peng, Xue He
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref
  25. EZH2 at the epigenetic–immune interface: a dual-axis framework for tumor immune evasion and precision combination immunotherapy
    Yang Bai, Huimin Chen, Ye Gu
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyCrossref